The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma
- PMID: 17145596
The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma
Abstract
Background and objectives: The presence of tumor-associated macrophages (TAM) is a prognostic factor for survival in follicular lymphoma (FL). Overexpression and/or activation of the signal transducer and activator of transcription 1 (STAT1) in these TAM have also been observed. The aim of this study was to determine the extent to which macrophages are present in FL and to investigate the expression of STAT1 in these cells.
Design and methods: We retrospectively analyzed 211 patients with distinct stages and grades of FL. Expression of the CD68 proteins, chosen as a marker for macrophages, and STAT1 was quantified by immunohistochemistry and double immunofluorescence.
Results: Automated determinations revealed the presence of CD68-positive macrophages in all FL tissues studied (mean 57.6+/-45.1 cells/field), while STAT1 protein was expressed in 29.94% of cases. Double-fluorescence staining confirmed that STAT1 protein co-localized exclusively with CD68, indicating the presence of a subset of STAT1-expressing TAM localized principally in the vicinity of tumor cells. Multivariate analysis showed that, besides the Follicular Lymphoma International Prognostic Index (FLIPI) classification, expression of STAT1 was an important independent prognostic factor for shorter overall survival in FL.
Interpretation and conclusions: These results demonstrate the presence of STAT1-expressing TAM in FL and their association with an adverse outcome, thus emphasizing the relevance of non-tumor cells in the control of the growth and survival of lymphoma cells.
Similar articles
-
A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.Clin Cancer Res. 2007 Oct 1;13(19):5784-9. doi: 10.1158/1078-0432.CCR-07-0778. Clin Cancer Res. 2007. PMID: 17908969
-
Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma.Hum Pathol. 2011 Apr;42(4):552-7. doi: 10.1016/j.humpath.2010.08.015. Epub 2011 Jan 15. Hum Pathol. 2011. PMID: 21237493
-
High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial.J Clin Oncol. 2008 Jan 20;26(3):440-6. doi: 10.1200/JCO.2007.12.8298. Epub 2007 Dec 17. J Clin Oncol. 2008. PMID: 18086798 Clinical Trial.
-
Prognosis of follicular lymphomas.Hematol Oncol. 2006 Jun;24(2):64-72. doi: 10.1002/hon.772. Hematol Oncol. 2006. PMID: 16514592 Review.
-
Implications of the tumor microenvironment on survival and disease response in follicular lymphoma.Curr Opin Oncol. 2010 Sep;22(5):424-30. doi: 10.1097/CCO.0b013e32833d5938. Curr Opin Oncol. 2010. PMID: 20679770 Review.
Cited by
-
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.Nat Rev Cancer. 2020 Nov;20(11):662-680. doi: 10.1038/s41568-020-0285-7. Epub 2020 Aug 4. Nat Rev Cancer. 2020. PMID: 32753728 Review.
-
JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens.Front Bioeng Biotechnol. 2023 Feb 23;11:1110765. doi: 10.3389/fbioe.2023.1110765. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 36911202 Free PMC article. Review.
-
Angiotensin-converting enzyme expression of the lymphoma-associated macrophages in the lymph nodes of Hodgkin's disease.J Natl Med Assoc. 2007 Nov;99(11):1243-4, 1246-7. J Natl Med Assoc. 2007. PMID: 18020099 Free PMC article.
-
Anti-tumour strategies aiming to target tumour-associated macrophages.Immunology. 2013 Feb;138(2):93-104. doi: 10.1111/imm.12023. Immunology. 2013. PMID: 23113570 Free PMC article. Review.
-
Prognostic factors in low-grade non-Hodgkin lymphomas.Curr Hematol Malig Rep. 2009 Oct;4(4):202-10. doi: 10.1007/s11899-009-0027-0. Curr Hematol Malig Rep. 2009. PMID: 20425409 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials
Miscellaneous